Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 24;14:17588359211070643. doi: 10.1177/17588359211070643

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Relationship between pretreatment mutational parameters and therapeutic response in 41 patients. (a) Box plot depicting the relationship between pretreatment CCF levels and clinical response. Each dot corresponds to one sample. (b) Correlation between TMB levels and therapeutic response. (c) Pretreatment VAF stratified by objective response (PR and SD versus PD) was not significantly associated with response in all patients. The horizontal bar represents the mean, the box represents the 25th and 75th percentiles, and whiskers ± 1.5 × interquartile range (IQR). (d) Pretreatment maximum VAF was not significantly associated with ORR in RECIST responders and nonresponders (p = 0.19). (e) There was no statistically significant difference between CNI levels and clinical benefit. (f), (g), and (h) The correlation between burden of tumor copy number changes (CNV, CNgain, and CNloss) and clinical benefit in all patients.